Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. | Zendy

Akira Matsumori | Zendy; Tetsuo Shioi | Zendy; Toshiyuki Yamada | Zendy; Shigeo Matsui | Zendy; S Sasayama | Zendy

Open Access

Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure.

Author(s) -

Akira Matsumori,

Tetsuo Shioi,

Toshiyuki Yamada,

Shigeo Matsui,

S Sasayama

Publication year - 1994

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.89.3.955

Subject(s) - medicine , heart failure , inotrope , cytokine , tumor necrosis factor alpha , proinflammatory cytokine , lipopolysaccharide , contractility , whole blood , stimulation , endocrinology , immunology , pharmacology , inflammation

Vesnarinone, a quinolinone derivative, is a recently synthesized positive inotropic agent that has been shown to dramatically improve the survival of patients with heart failure. However, the mechanism of action of vesnarinone remains unknown. Reversible neutropenia complicated with vesnarinone therapy suggests that vesnarinone may modulate the production of cytokines. Because tumor necrosis factor (TNF)-alpha and other cytokines have been shown to depress myocardial contractility, we investigated the effects of vesnarinone on the production of various cytokines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research